Clinical trials: Antipsychotic
Schizophrenia, Schizoaffective Disorder
A Trial to Explore Acceptance and Performance of Using a Digital Medicine System With Healthcare Professionals and Adults With Schizophrenia, Schizoaffective Disorder, or First Episode Psychosis on an Oral Atypical Antipsychotic
Digital medicine systems (DMS) have been designed to assist individuals with the management of their daily health, wellness, and medication use.
- Conditions
- Schizophrenia, Schizoaffective Disorder, First Episode Psychosis
- Trial name
- NCT03568500
- Testing
- Digital Medicine System, Aripiprazole, Olanzapine
- Where
- 5 sites in United Kingdom
- Volunteers
- 44 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Obsessive-Compulsive Disorder
Risperidone or Cognitive-Behavioral Therapy for Improving Medication Treatment for Obsessive-compulsive Disorder
This study will compare the short- and long-term effectiveness of two common therapies in improving serotonin reuptake inhibitor treatment in people with obsessive-compulsive disorder.
- Trial name
- NCT00389493
- Testing
- Risperidone, Exposure/ritual prevention therapy (EX/RP)
- Where
- 2 sites in United States
- Volunteers
- 100 people
- Sponsor
- New York State Psychiatric Institute
Schizophrenia, Schizoaffective Disorder
Efficacy and Safety of Two Atypical Antipsychotics vs. Placebo in Patients With an Acute Exacerbation of Either Schizophrenia or Schizoaffective Disorder
A study to evaluate the efficacy and safety of two atypical antipsychotics vs. placebo in patients with an acute exacerbation of either schizophrenia or schizoaffective disorder
- Trial name
- NCT00061802
- Testing
- risperidone, quetiapine
- Where
- 13 sites in United States, India and 1 more
- Volunteers
- 225 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
First Episode Psychosis
Recovery With Exogenous Ketones and Antipsychotics
The RECAP project will evaluate the clinical and metabolic effects of adding exogenous ketones to antipsychotic (AP) treatment in young adults with a first episode of psychosis (FEP).
- Trial name
- RECAP (NCT07122531)
- Testing
- Medium chain triglyceride oil
- Where
- Canada
- Volunteers
- 15 people
- Sponsor
- Université de Sherbrooke
Schizophrenia
Treatment of Neuroleptic Induced Acute Akathisia With Trazodone
Administration of trazodone for the treatment of neuroleptic induced acute akathisia in a cross-over fashion of 6 days duration. 3 days of placebo and 3 days of trazodone.
- Trial name
- NCT00659919
- Testing
- Trazodone
- Where
- Israel
- Volunteers
- 13 people
- Sponsor
- BeerYaakov Mental Health Center
Behavior Disorders, Neuroleptic
Clinical Situations Leading to the Prescription of Neuroleptics by General Practitioner in the Elderly. Practice Survey
Behavioral disorders of psychiatric or neurological origin in the elderly are an emerging public health problem. Its management can include a prescription of psychotropic drugs (anxiolytics, hypnotics, neuroleptics…
- Trial name
- NEUGERPRAT (NCT03116100)
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Centre Hospitalier Universitaire, Amiens
Hyperprolactinemia, Weight Gain
Reversal of Antipsychotic-Induced Hyperprolactinemia, Weight Gain, Hyperglycemia and Dyslipidemia
This is a prospective, open-label study to evaluate the efficacy and safety in reducing antipsychotic-induced hyperprolactinemia, weight gain, and dyslipidemia by aripiprazole.
- Conditions
- Hyperprolactinemia, Weight Gain, Dyslipidemia
- Trial name
- NCT00541554
- Testing
- Abilify (aripiprazole)
- Sponsor
- Genovate Biotechnology Co., Ltd.,
Metabolic Disturbance, Schizophrenia
Does GLP-1RA Prevent Deterioration of Metabolic State in Prediabetic and Diabetic Patients Treated With Antipsychotic Medication?
Background and objective: Clozapine and olanzapine are some of the most effective antipsychotic drugs, but unfortunately, both drugs induce weight gain and conveys a high degree of metabolic disturbances.
- Conditions
- Metabolic Disturbance, Schizophrenia, Type 2 Diabetes, Clozapine
- Trial name
- NCT04892199
- Testing
- Semaglutide, 1.34 mg/mL
- Where
- 3 sites in Denmark
- Volunteers
- 104 people
- Sponsor
- Anders Fink-Jensen, MD, DMSci
Schizophrenia, Schizoaffective Disorder
A Trial Comparing Risperidone Long-Acting Injection With Oral Antipsychotic in the Treatment of Early Psychosis
The purpose of this study is to evaluate the effectiveness, safety and tolerability of risperidone long-acting injection (LAI) versus oral antipsychotics in participants with recent onset psychosis (abnormal thinking and/or…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Psychotic Disorders
- Trial name
- NCT00246259
- Testing
- Risperidone long-acting injection (LAI), Oral Antipsychotic
- Where
- 11 sites in Canada
- Volunteers
- 77 people
- Sponsor
- Janssen-Ortho Inc., Canada
Schizophrenia
Observe Real-life Allocation of Atypical Antipsychotics in the Acute Inpatient Management of Schizophrenia
The primary objective of this Non- Interventional Study (NIS) is to describe the use of atypical antipsychotics in subjects with Schizophrenia during the hospitalisation due to acute psychotic episode by evaluation of drug, dose…
- Trial name
- RECONNECT-S (NCT01544608)
- Where
- 7 sites in Egypt, Saudi Arabia and 1 more
- Volunteers
- 1,076 people
- Sponsor
- AstraZeneca
Normal Volunteers
Evaluation of Negative Symptoms and Cognitive Function After Administration of Antipsychotics in Healthy Volunteer
The aim of the study is to investigate the negative symptoms and cognitive function after administration of antipsychotics in healthy volunteer.
- Trial name
- NCT01185418
- Testing
- risperidone, aripiprazole, haloperidol
- Where
- South Korea
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Chonbuk National University Hospital
Schizophrenia
Antipsychotic Medication Extended Dosing Study
In patients stabilized on their antipsychotic and demonstrating evidence of good clinical response, there will not be a significant change in symptoms if their medication is decreased to every 2 days rather than daily.
- Trial name
- NCT00431574
- Testing
- dosing
- Where
- Canada
- Volunteers
- 120 people
- Sponsor
- Centre for Addiction and Mental Health
Schizophrenia
Efficacy of Selegiline in Negative Symptoms of Schizophrenia
Antipsychotic drugs are effective in treating the positive symptoms of schizophrenia; however their efficacy in treating negative symptoms is limited.
- Trial name
- NCT00456976
- Testing
- Selegiline
- Where
- Iran
- Volunteers
- 70 people
- Sponsor
- Tabriz University
Affective Disorder, Psychosis
Value of Gym-based Exercise Training for Young Adults Receiving Antipsychotic Medication: The Vega Trial
This is a multicentre, pragmatic, randomised controlled trial to estimate the effect of a 4-month gym-based exercise training program on 1) patient-rated personal recovery (primary outcome), 2) Health-related quality of life…
- Trial name
- Vega (NCT05461885)
- Testing
- Supervised exercise
- Where
- 4 sites in Denmark
- Volunteers
- 226 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Obesity
Cognitive Behavioral Therapy for Obesity
The purpose of this pilot study is to assess patient accessibility, interest and response in order to design an adequately powered study to compare brief, group cognitive behavioral therapy (CBT) for weight loss to usual care in…
- Trial name
- NCT00569517
- Testing
- CBT, educational
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- US Department of Veterans Affairs
Schizophrenia, Psychotic Disorders
A Study of the Effectiveness and Safety of Risperidone Compared With Haloperidol and Placebo in Patients With Chronic Schizophrenia
The purpose of the study is to evaluate the effectiveness and safety of different doses of risperidone (an antipsychotic medication) compared with placebo and with a fixed 20 mg/day dose of a standard antipsychotic, haloperidol…
- Trial name
- NCT00249132
- Testing
- risperidone
- Volunteers
- 523 people
- Sponsor
- Janssen, LP
Schizophrenia
Randomized Withdrawal Study in Patients With Schizophrenia
The purpose of this research is to evaluate the efficacy of dosing iloperidone long-acting injection (LAI) compared to placebo in preventing the exacerbation of symptoms in patients with schizophrenia.
- Trial name
- NCT06961968
- Testing
- iloperidone
- Where
- 22 sites in United States
- Volunteers
- 400 people
- Sponsor
- Vanda Pharmaceuticals
Bipolar Depression
Treatment Resistant Bipolar Depression
To determine if adding Escitalopram to current mood stabilizer (MS) or atypical antipsychotic (AA) will improve in rates similar to or better than adding a placebo (inactive pill)in resistant bipolar patients.
- Trial name
- NCT00272025
- Testing
- Escitalopram
- Where
- Canada
- Volunteers
- 1 people, healthy volunteers welcome
- Sponsor
- Queen's University
Attenuated Psychosis Syndrome
Fluoxetine vs Aripiprazole Comparative Trial (FACT)
We are conducting a randomized, 24-week, double-blind study, comparing fluoxetine with aripiprazole in 48 patients with attenuated positive symptoms at a level of at least moderate severity.
- Trial name
- FACT (NCT02357849)
- Testing
- Aripiprazole, Fluoxetine
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Northwell Health
Schizophrenia, Antipsychotics
The Study of Atypical Antipsychotics-induced Metabolic Disturbances
Schizophrenia is one of the most severe mental illnesses. The antipsychotic drugs, introduced in early 1950s, have revolutionized the treatment of schizophrenia.
- Trial name
- NCT00937755
- Where
- Taiwan
- Volunteers
- 80 people
- Sponsor
- Taipei Medical University Hospital